Browse articles from EyeWorld.org related to glaucoma. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
Two glaucoma specialists spoke with EyeWorld about the current role of SLT, as well as products in development and further research in the glaucoma laser space.
While glaucoma treatment is shifting toward a more interventional approach, two physicians said the use of drop therapy is alive and well. It is trending toward being an adjunctive therapy as more ophthalmologists are beginning to figure out what pharmaceutical and procedural combinations best suit their patients.
Many MIGS procedures are proving useful and accessible not just to the glaucoma specialist but to comprehensive ophthalmologists as well. Two ophthalmologists discussed who should be performing glaucoma surgery, as well as ways to learn and stay fresh with some of these techniques.
While ophthalmologists agree that glaucoma drops are not likely to go extinct as part of glaucoma management, recent innovation continues to shift their place in many physicians’ glaucoma treatment algorithm. One of these disruptive innovations is sustained drug delivery. Two experts weighed in on the topic.
➤ Fast Track Designation granted for investigational retinitis pigmentosa therapy ➤ Three-month data for first-in-class dual inflammasome inhibitor for geographic atrophy ➤ Clinical updates for sustained-release drug implant treating glaucoma ➤ Gene therapy program receives Rare Pediatric Disease Designation ➤ Study: lasting effect of multifocal contact lenses for myopia progression ➤ ASCRS news and events
➤ NDA submitted for epithelium-on crosslinking therapy ➤ Positive results in Phase 2 trial for first-in-class therapy for acute optic neuritis ➤ Study: long-term, real-world findings evaluating standalone canaloplasty and trabeculotomy ➤ Phase 1b study evaluating sozinibercept for DME published ➤ Phase 2 study for topical dry AMD therapy begins ➤ FDA clears IND for gene therapy targeting Stargardt disease ➤ ASCRS news and events
In June 2024, the FDA approved the FSYX Ocular Pressure Adjusting Pump by Balance Ophthalmics, making it the first non-surgical, non-pharmaceutical, IOP-lowering therapy for patients with open angle glaucoma. Physicians shared how they are excited about being able to lower IOP safely in normal tension glaucoma patients with accompanying nocturnal IOP elevations.
Glaucoma Editor Manjool Shah, MD, previewed the articles in the section and shared his thoughts on using the past to guide the future. “However, we should not be deluded into thinking our feet are planted in cement, holding us back from achieving new heights,” he said.
In treating glaucoma, educating the patient about their disease is a crucial step. In addition to finding an appropriate treatment plan, it’s important for the patient to understand the nature of their disease. Two specialists discussed how they help patients understand glaucoma and how testing and treatments options play in.
➤ Topline results for non-steroidal immunomodulator for postop inflammation ➤ Pilot study describes use of prosthetic device for treatment of dry eye ➤ First patient dosed in Phase 3 trial investigating wet AMD treatment ➤ Acquisition and partnership news ➤ ASCRS news and events
Get the latest ophthalmology news delivered to your inbox every Friday.